Toggle light / dark theme

When conventional non-invasive treatments for psychiatric diseases fail, clinicians inevitably have to consider brain surgery. However, brain surgery for psychiatric diseases has long been taboo among the general public due to the infamous history of lobotomy. Thankfully, advancements in brain surgery in recent years are changing the narrative.

Bilateral capsulotomy, more commonly known as , is a form of that has been garnering attention in treating treatment-resistant or refractory (OCD). Patients with refractory OCD experience a debilitating degree of repetitive behaviors and thoughts that they are unable to control, thus downgrading their quality of life.

A group of researchers from South Korea demonstrated that a novel non-invasive bilateral capsulotomy called magnetic resonance-guided focused ultrasound (MRgFUS) capsulotomy is efficacious and safe in treating refractory OCD for up to two years. MRgFUS capsulotomy non-invasively and precisely ablates tissues in the brain region of interest. However, the sustained efficacy of this treatment option was unclear.

A groundbreaking study just revealed AI outperforming human doctors at medical diagnosis — but before you panic, this could be the best news yet for healthcare.

This hits personally for me. From my kiddo’s misdiagnosed case of hives to my own health struggles with multiple doctors, I’ve seen firsthand why we need AI to empower (not replace) medical professionals. I’m sure I’m not the only one.

In this video, we’ll explore:

-The shocking study results (90% AI accuracy vs 74% human doctors)
–Why this means more human connection, not less.
–How AI could transform patient care for the better.
–The real reason doctors aren’t fully utilizing AI yet.

The future of healthcare isn’t AI vs doctors — it’s both working together to provide better care than either could alone. Let’s dive into what this means for you and your family’s healthcare.

The dream of many – to try the taste through a monitor – is getting closer.

Remove ads and unlock PREMIUM content

A team of biomedical engineers and virtual reality experts has developed a groundbreaking lollipop-shaped interface that simulates taste in virtual reality.

A basic function of cells is that they act in response to their environments. It makes sense, then, that a goal of scientists is to control that process, making cells respond how they want to what they want.

One avenue for this ambition is , which function like ignition slots on a cell, requiring keys—such as specific hormones, drugs, or antigens—to start up specific cellular activities. There are already synthetic receptors that give us some control over this sequence of events, most famously the chimeric antigen receptors used in CAR-T cell cancer therapy. But existing synthetic receptors are limited in the variety of keys they can accept and the activities they can trigger.

Now, detailed in a paper published in Nature, Stanford researchers have developed a new synthetic receptor that accommodates a broader range of inputs and produces a more diverse set of outputs.

Multisectoral approaches for combating antimicrobial resistance — dr. amal al-maani — director general, diseases surveillance & control, ministry of health oman.


Dr. Amal Al-Maani, MD is Director General for Diseases Surveillance and Control at the Ministry of Health of Oman (https://moh.gov.om/en/hospitals-direc…), senior consultant in pediatric infectious diseases in the Sultanate, and is the focal point for the Global Antimicrobial Resistance (AMR) Surveillance System (GLASS) and is responsible for Oman national surveillance system for AMR (OMASS) and the national Infection Prevention and Control (IPC) program.

Dr. Al-Maani completed her medical degree from Sultan Qaboos University, Oman and passed the London School diploma in tropical Medicine and Hygiene (DTM\&H) during her internship period. Followed by her postgraduate training at the University of Toronto, she achieved her fellowship in pediatric infectious diseases from the Royal College of Physicians and Surgeons, Canada. She has the Certificate In Infection Control from the Certification Board of Infection Control \& Epidemiology, a certificate in global health from Dalla Lana School of Public Health the Centre for International Health in the University of Toronto (UFT), and the Patient Safety \& Quality Improvement certificate from the center for patient safety in UFT.

Dr. Al-Maani has participated in many national and International Conferences and presented many papers. She received Dr Susan King Award at the Canadian AMMI conference 2011 and in 2021 the WHA Sasakawa health development award for her work in AMR and IPC. She published many papers in the field of infectious diseases and infection control with a focus on Antimicrobial resistance and emerging resistant pathogens. She had been a co-author in multiple positional statements for the International Society for Infectious Diseases (ISID) group in infection control, including most recently about the Global Antimicrobial Stewardship with a Focus on Low-and Middle-Income Countries and on the Prevention of Clostridioides.

#AntimicrobialResistance #AMR #AmalAlMaani #DiseasesSurveillance #MinistryOfHealth #Oman #SultanQaboosUniversity #WHO #WorldHealthOrganization #OneHealth #Antibiotics #Vaccines #TropicalMedicine #Hygiene #VancomycinResistantEnterococcus #MethicillinResistantStaphylococcus #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Autism is a neurodevelopmental disorder characterized by difficulties in communication and social behavior. Approximately 20% of cases are linked to a specific genetic mutation, but the origin of the remaining 80%, known as idiopathic autism, remains a mystery.

A team of scientists led by Drs. Raúl Méndez and Xavier Salvatella at the Institute for Research in Biomedicine (IRB Barcelona) has identified a that explains why certain alternations of the neuronal protein CPEB4 are associated with idiopathic autism.

The study is based on previous work published in 2018 that identified CPEB4 as a key protein in the regulation of neuronal proteins related to autism.

Researchers at Baylor College of Medicine, Stanford University School of Medicine and collaborating institutions report in the journal Cell the discovery of BHB-Phe, a novel compound produced by the body that regulates appetite and body weight through interactions with neurons in the brain.

Until now, BHB has been known as a compound produced by the liver to be used as fuel. However, in recent years, scientists have found that BHB increases in the body after fasting or exercise, prompting interest in investigating potential beneficial applications in obesity and diabetes.

In the current study, the team at Stanford University led by co-corresponding author Dr. Jonathan Z. Long, associate professor of pathology, discovered that BHB also participates in another metabolic pathway. In this case, an enzyme called CNDP2 joins BHB to amino acids. Furthermore, the most abundant BHB-amino acid, BHB-Phe, can influence body weight and metabolism in animal models.

A new Science Advances study demonstrates a vaccine for cancer immunotherapy that would speed up the efficiency of messenger RNA translation in cytoplasm—and effectively inhibited tumor growth.